Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Kiniksa Pharmaceuticals International's current 3-Year Share Buyback Ratio was -3.10%.
The historical rank and industry rank for Kiniksa Pharmaceuticals International's 3-Year Share Buyback Ratio or its related term are showing as below:
KNSA'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -13.3 Med: -5.4 Max: -1.1
Current: -3.1
During the past 10 years, Kiniksa Pharmaceuticals International's highest 3-Year Share Buyback Ratio was -1.10%. The lowest was -13.30%. And the median was -5.40%.
KNSA's 3-Year Share Buyback Ratio is ranked worse than 54.87% of 647
companies
in the Drug Manufacturers industry
Industry Median: -2.1
vs KNSA: -3.10
Kiniksa Pharmaceuticals International (NAS:KNSA) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Kiniksa Pharmaceuticals International 3-Year Share Buyback Ratio Related Terms
KNSA vs AMRX, LQDA, LNTH: 3-Year Share Buyback Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiniksa Pharmaceuticals International 3-Year Share Buyback Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals International's 3-Year Share Buyback Ratio falls into.
Kiniksa Pharmaceuticals International 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -3.10 mean?
Kiniksa Pharmaceuticals International (KNSA) has a 3-Year Share Buyback Ratio of -3.10 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Kiniksa Pharmaceuticals International and its competitors. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #355 out of 647 companies in the Drug Manufacturers industry, placing it in the top 54.9%.
Is Kiniksa Pharmaceuticals International's 3-Year Share Buyback Ratio too high?
Kiniksa Pharmaceuticals International's current 3-Year Share Buyback Ratio is -3.10. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #355 out of 647 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's 3-Year Share Buyback Ratio compare to AMRX and LQDA?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #355 out of 647 companies for 3-Year Share Buyback Ratio. This places Kiniksa Pharmaceuticals International in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Year Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Kiniksa Pharmaceuticals International and its competitors. Kiniksa Pharmaceuticals International's current 3-Year Share Buyback Ratio is -3.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $55.74, compared to a current price of $76.18 — trading 36.7% above its estimated fair value. The current 3-Year Share Buyback Ratio is -3.10. Kiniksa Pharmaceuticals International's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current 3-Year Share Buyback Ratio is -3.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued.
The current stock price of $76.18 is trading 36.7% above its estimated GF Value™ of $55.74.
GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.
Key valuation signals for KNSA:
3-Year Share Buyback Ratio: -3.10
GF Value™: $55.74 vs. price of $76.18 (36.7% above fair value)
No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score
Get the complete analysis for KNSA
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNSA has been successfully added to your 
